Experts discuss PPI use for GI protection in patients on antithrombotics, highlighting risk factors, dosing, drug ...

Aims Clopidogrel is the most commonly prescribed thienopyridine as part of dual anti-platelet therapy for the treatment of ...

Major bleeding was low overall, but the findings align with other large datasets showing greater risk with rivaroxaban.

Platelets play an important role in atherothrombotic disease. The currently available antiplatelet drugs target key steps of platelet activation including thromboxane A 2 synthesis, ADP-mediated ...

High blood pressure stands among the leading causes of stroke, yet many people fail to recognize the critical importance of ...

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

The clot-dissolving medication, alteplase, improved stroke patients' recovery by more than 50% when given up to 24 hours after the beginning of an ischemic stroke, according to preliminary ...

The FDA reviews drug approval decisions that are expected in March 2025. The FDA is reviewing the application for bentracimab for use as a ticagrelor reversal agent in patients with uncontrolled ...

Dr MKO AbimbolaDiabetes is a long-term condition caused by defi­ciency in quantity or function of insulin, the chemical controlling the level of sugar in the blood. People with diabetes par­ticularly ...

A new study has found that the clot-dissolving drug alteplase can significantly improve stroke recovery even when given up to ...

Novartis has announced its acquisition of Anthos Therapeutics, a Boston-based biopharmaceutical company focused on developing abelacimab, an inve ...

Compared with rivaroxaban, abelacimab is associated with fewer bleeding events in patients with AF and moderate to high risk for stroke.